Results 161 to 170 of about 10,125,713 (289)

Comment on "Unveiling Resmetirom: A Systematic Review and Meta-Analysis on Its Impact on Liver Function and Safety in Non-Alcoholic Steatohepatitis Treatment". [PDF]

JGH Open
Ruzayqat R.
europepmc   +1 more source

Effect of interdisciplinary obesity care on metabolic markers and body weight in people with type 2 diabetes in a rural setting: A randomised controlled trial

Clinical Obesity, Volume 15, Issue 2, April 2025.
Summary Management of type 2 diabetes includes medications that can unintentionally increase obesity and insulin resistance. This unblinded, single‐centre, randomised controlled trial focused on rural Australian adults with type 2 diabetes (aged 18–75 and body mass index [BMI] >30 kg/m2), measuring the effectiveness of a tailored interdisciplinary ...
Giuliana O. Murfet, Iain K. Robertson, Sharon P. Luccisano, Michelle L. Kilpatrick   +3 more
wiley   +1 more source

14-Deoxy-11,12-didehydroandrographolide Attenuates Lipotoxicity and Non-Alcoholic Steatohepatitis Through Restoration of Autophagy and Reduction in Oxidative Stress. [PDF]

Int J Mol Sci
Lo CW, Chen YC, Liu KL, Li CC, Lii CK, Chan HH, Chen CC, Yang YC, Chen HW.   +8 more
europepmc   +1 more source

Liver Organoids: From Disease Modelling to Regenerative Medicine

Cell Proliferation, EarlyView.
Liver organoids provide a versatile platform for disease modelling and drug discovery, leveraging stem cells and engineering techniques. They bridge research and clinical applications, offering significant potential for advancing precision medicine and regenerative therapies for liver diseases.
Tiepeng Wang, Xiaotian Qu, Jinhong Si, Junkang Meng, Ting Zhang, Shuliang Niu   +5 more
wiley   +1 more source

Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou, Christoforos K. Travlos, Lucas Lage Marinho, Thomas A. Mavrakanas, João Pedro Ferreira, Abhinav Sharma   +5 more
wiley   +1 more source

Smilax glabra flavonoids ameliorate non-alcoholic steatohepatitis by regulating PKM2-dependent glycolysis and suppressing AIM2 inflammasome activation. [PDF]

Front Immunol
Pang Z, Ding Y, Hu L, Ding S, Cai Z, Wang D.   +5 more
europepmc   +1 more source

Efficacy of Luseogliflozin Added to Semaglutide in Patients With Metabolic Dysfunction‐Associated Steatohepatitis and Type 2 Diabetes Mellitus: A Randomised, Open‐Label Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Type 2 diabetes drives the progression of metabolic dysfunction‐associated steatohepatitis (MASH). We evaluated whether antidiabetic therapy, specifically adding sodium–glucose cotransporter 2 (SGLT2) inhibitor to a glucagon‐like peptide‐1 receptor agonist (GLP‐1RA), improves liver histology in adults with biopsy‐proven MASH and type 2 ...
Teruki Miyake, Osamu Yoshida, Shinya Furukawa, Masashi Hirooka, Masanori Abe, Yoshio Tokumoto, Ayumi Kanamoto, Takao Watanabe, Ryo Yano, Yuki Okazaki, Atsushi Yukimoto, Yoshiko Nakamura, Eiji Takeshita, Teru Kumagi, Yoichi Hiasa   +14 more
wiley   +1 more source

Dietary Soybean vs. Palm Oils Differ in Effects on Liver Fat in Adults With MAFLD: A 16‐Week, Double‐Masked, Randomized Controlled Trial

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Background Dietary linoleic acid (LA)‐rich oils reduce liver fat in healthy adults who are not otherwise undergoing weight loss strategies. Effects on the liver fat in adults with fatty liver disease are unknown. Objective The objective of this randomized double‐masked controlled trial was to compare the effects of a dietary soybean oil (SO ...
Martha A. Belury, Rachel M. Cole, Ai Ni, Arunark Kolipaka, Manjunathan Nanjappa, Kristin Thompson, Ali Kalhori, Stephan Zarich, Rolando E. Choriego, Rafael Jimenez‐Flores, Na Li   +10 more
wiley   +1 more source

Empagliflozin attenuates dexamethasone-induced non-alcoholic steatohepatitis by regulation of ferroptosis, inflammation and autophagy. [PDF]

Front Pharmacol
Alharbi NS, Abdelmageed ME, Nader MA, Serrya MS.   +3 more
europepmc   +1 more source

Non-alcoholic steatohepatitis incidence in patients with psoriasis vulgaris. [PDF]

Wien Med Wochenschr
Elhanon HM, Atallah RB, Eldahshan RM, Mohamed SED, Elsaie ML.   +4 more
europepmc   +1 more source